IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v35y2017i1d10.1007_s40273-016-0440-x.html
   My bibliography  Save this article

Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Author

Listed:
  • Paul Tappenden

    (ScHARR, University of Sheffield)

  • Sue Harnan

    (ScHARR, University of Sheffield)

  • Shijie Ren

    (ScHARR, University of Sheffield)

  • Praveen Thokala

    (ScHARR, University of Sheffield)

  • Ruth Wong

    (ScHARR, University of Sheffield)

  • Clara Mukuria

    (ScHARR, University of Sheffield)

  • Clare Green

    (Southampton General Hospital and Hampshire Hospitals Foundation Trust)

  • Simon Pledge

    (Sheffield Teaching Hospitals NHS Foundation Trust)

  • John Tidy

    (Sheffield Teaching Hospitals NHS Foundation Trust)

Abstract

As part of its Single Technology Appraisal process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer of olaparib (AstraZeneca) to submit evidence on the clinical and cost effectiveness of olaparib for the maintenance treatment of BRCA1/2 mutated (BRCAm), platinum-sensitive relapsed (PSR) ovarian, fallopian tube and peritoneal cancer in people whose relapsed disease has responded to platinum-based chemotherapy. The Evidence Review Group (ERG) produced a critical review of the evidence contained within the company’s submission (CS) to NICE. The clinical evidence related to one phase II, double-blind randomised controlled trial that recruited 265 patients with PSR serous ovarian cancer (OC) regardless of BRCAm status. Patients received olaparib 400 mg twice daily (b.i.d.) or matched placebo. In the whole population, the primary endpoint of progression-free survival (PFS) was met (hazard ratio [HR] 0.35; 95 % confidence interval [CI] 0.25–0.49, p

Suggested Citation

  • Paul Tappenden & Sue Harnan & Shijie Ren & Praveen Thokala & Ruth Wong & Clara Mukuria & Clare Green & Simon Pledge & John Tidy, 2017. "Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based C," PharmacoEconomics, Springer, vol. 35(1), pages 97-109, January.
    • Handle: RePEc:spr:pharme:v:35:y:2017:i:1:d:10.1007_s40273-016-0440-x
    DOI: 10.1007/s40273-016-0440-x
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40273-016-0440-x
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40273-016-0440-x?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:35:y:2017:i:1:d:10.1007_s40273-016-0440-x. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.